Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alzamend Neuro, Inc.

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VariePsichiatriaSalute

14 comunicati stampa

Guarda tutti i comunicati
19/02/2025
Multimedialità
Industria
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
15/01/2025
Eventi
Industria
Psichiatria
Salute
Sanità
Scienza
Farmaceutica
Alzamend Neuro to Present at the Sequire Investor Summit
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
18/12/2024
Eventi
Industria
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
12/12/2024
Scienza
Farmaceutica
Sanità
Salute
Psichiatria
Medicina - Varie
Mercato azionario
Industria
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
19/11/2024
Scienza
Farmaceutica
Sanità
Salute
Psichiatria
Medicina - Varie
Industria
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
16/10/2024
Industria
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
15/10/2024
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Psichiatria
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
10/10/2024
Web e Social Network
Eventi
Psichiatria
Attrezzature medico-sanitarie
Salute
Farmaceutica
Biotecnologia
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
19/08/2024
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0
12/08/2024
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder 
Fonte
Alzamend Neuro, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0